
CUE: The Data’s In… Kind Of
Cue Biopharma (CUE) released preliminary Phase 1A data this morning. There are several incremental updates. Here are the key takeways…
Cue Biopharma (CUE) released preliminary Phase 1A data this morning. There are several incremental updates. Here are the key takeways…
Cue Biopharma (CUE) is set to present interim Phase 1 data for CUE-101, which could start a rally that ulimately sees shares rise to $150. Here’s why…
Cue Biopharma (CUE) is set to report Q1 2020 results. Here are six reasons why I expect positive data to come imminently and why shares could rally to $150+
Shares of Cue Biopharma (CUE) are up more than 100% from our entry. But I’m letting this winner ride, as four relevant biotech deals point to another 97% to 637% upside to current prices. Here are all the details…
Five key takeaways from Cue Biopharma’s Q1 2019 report, including the list of catalysts management believes will result in 2019 being a “transformational” year…
Here are three reasons why today’s FDA approval to enter the clinic with CUE-101 for HPV-associated cancers is significant, including two not so obvious reasons. Plus, a list of catalysts for 2019…